

Supplementary Table 1. EMM changes from baseline to follow-ups at 3, 6, and 9 months in non-continuous glucose monitoring users

Outcomes	EMM (95% CI)		P value ^a
	Control group	Intervention group	
HbA1c, %			
3 months	-0.11 (-0.19 to -0.03)	-0.27 (-0.36 to -0.18)	0.184
6 months	-0.20 (-0.28 to -0.12)	-0.34 (-0.44 to -0.24)	0.292
9 months	-0.20 (-0.29 to -0.11)	-0.46 (-0.56 to -0.36)	0.041
GA, %			
3 months	-0.42 (-0.80 to -0.04)	-1.03 (-1.45 to -0.61)	0.264
6 months	0.28 (-0.14 to 0.70)	-1.40 (-1.85 to -0.95)	0.005
9 months	0.13 (-0.33 to 0.59)	-2.62 (-3.08 to -2.16)	<0.001
FBS, mg/dL			
3 months	-3.38 (-10.73 to 3.97)	-20.85 (-29.73 to -11.97)	0.105
6 months	-3.90 (-12.12 to 4.32)	-11.26 (-20.93 to -1.59)	0.588
9 months	-10.44 (-20.43 to -0.45)	-14.32 (-29.02 to 0.38)	0.541
GA/HbA1c ratio			
3 months	-0.01 (-0.05 to 0.03)	-0.03 (-0.07 to 0.01)	0.533
6 months	0.07 (0.02 to 0.12)	-0.01 (-0.06 to 0.04)	0.259
9 months	0.10 (0.05 to 0.15)	-0.12 (-0.17 to -0.07)	0.003

EMM changes from baseline to each follow-up were analyzed after adjusting for age, sex, and body mass index.

EMM, estimated marginal mean; CI, confidence interval; HbA1c, glycosylated hemoglobin; GA, glycoalbumin; FBG, fasting blood glucose.

^aP values for group × time interaction.